Dana-Farber Cancer Institute Launches Dana-Farber Pathways Using Via Oncology’s Platform

Share Article

Adoption of industry-leading pathway tools to assist in elevating patient cancer care

The Dana-Farber Cancer Institute is advancing patient care by leveraging its physician expertise, using the software toolsets from Via Oncology to create Dana-Farber Pathways.

Dana-Farber Pathways have been developed by the physician disease experts within Dana-Farber and are updated quarterly, or more often as needed, for new published data as well as for all available clinical trials at Dana-Farber. These oncology clinical pathways will support Dana-Farber-affiliated physicians by creating personalized, evidence-based care plans for each patient’s specific type and stage of cancer.

To launch its program, Dana-Farber chose Pittsburgh-based Via Oncology for its innovative clinical pathways platform. Dana-Farber will utilize Via’s proprietary clinical content authoring tool, PathBuildR, to author and update DFCI Pathways. The institute's oncologists will then access DFCI Pathways through the Via Portal, a point of care, patient specific decision support tool. Finally, Via will provide the platform and database for Dana-Farber’s reporting and analytics.

“Dana-Farber oncologists have the expertise and depth of knowledge to develop and maintain robust Dana-Farber pathways,” says Kathy Lokay, President and CEO of Via Oncology. “Via’s decision support and reporting platform will help them rapidly author their changes and deliver these point of care, patient specific pathways to their affiliated oncologists.”

“Our goal is to provide our extended network of caregivers with the latest, evidence-based standards of care, adaptable for each of their patient’s specific needs,” adds Dana-Farber Chief Quality Officer Dr. Joseph Jacobson. “Every person with cancer should have access to the most effective treatments available, and Dana-Farber Pathways will be an important part of making this happen.”


About Dana-Farber Cancer Institute

From achieving the first remissions in childhood cancer with chemotherapy in 1948, to developing the very latest new therapies, Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment.  It is the only center ranked in the top 4 of U.S. News and World Report’s Best Hospitals for both adult and pediatric cancer care.
Dana-Farber sits at the center of a wide range of collaborative efforts to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy.  Dana-Farber/Brigham and Women’s Cancer Center provides the latest in cancer care for adults; Dana-Farber/Boston Children's Cancer and Blood Disorders Center for children. The Dana-Farber/Harvard Cancer Center unites the cancer research efforts of five Harvard academic medical centers and two graduate schools, while Dana-Farber Community Cancer Care provides high quality cancer treatment in communities outside Boston’s Longwood Medical Area.  
Dana-Farber is dedicated to a unique, 50/50 balance between cancer research and care, and much of the Institute’s work is dedicated to translating the results of its discovery into new treatments for patients locally and around the world.  

About Via Oncology

Via Oncology, LLC is the cancer value management solution for medical, radiation and surgical oncologists. The Via Pathways span the continuum of cancer care including workup, diagnostics, treatment, symptom management, survivorship and advance care planning. Via Oncology also supports its cancer center customers through quality reporting, patient education, clinical trial accrual support and medical home tools. The Via Pathways are licensed by over 1,300 oncology providers in 23 states in community, hospital and academic based cancer centers. Learn more at http://www.viaoncology.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Kathy Lokay
Via Oncology
+1 412-204-1052
Email >
Follow >
Visit website